Immunotherapeutic Targets in Non-Small Cell Lung Cancer

Immunotherapeutic Targets in Non-Small Cell Lung Cancer Publisher Pubmed

Sadeghirad H¹ ; Bahrami T² ; Layeghi SM³ ; Yousefi H⁴ ; Rezaei M⁵ ; Hosseinifard SR³ ; Radfar P⁵ ; Warkiani ME⁵ ; Obyrne K⁶ ; Kulasinghe A¹

Show Affiliations

1. University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia
2. Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
3. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, LA, United States
5. School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW, Australia
6. Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia

Source: Immunology Published:2023

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy. © 2022 The Authors. Immunology published by John Wiley & Sons Ltd.

Related Docs

View other Related Docs

1. Tumor Immunology, Clinical Immunology (2022)

2. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)

3. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)

4. Advances in Therapeutic Targeting of Immune Checkpoints Receptors Within the Cd96-Tigit Axis: Clinical Implications and Future Perspectives, Expert Review of Clinical Immunology (2022)

5. The Prospect of Targeting T Cell Immunoglobulin and Mucin-Domain Containing-3 in Renal Cell Carcinoma Immunotherapy, Scandinavian Journal of Immunology (2022)

6. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)

7. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)

8. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (54)

Bagher Larijani (9)

Style	Citing Format
MLA	Sadeghirad H, et al.. "Immunotherapeutic Targets in Non-Small Cell Lung Cancer." Immunology, vol. 168, no. 2, 2023, pp. 256-272.
APA	Sadeghirad H, Bahrami T, Layeghi SM, Yousefi H, Rezaei M, Hosseinifard SR, Radfar P, Warkiani ME, Obyrne K, Kulasinghe A (2023). Immunotherapeutic Targets in Non-Small Cell Lung Cancer. Immunology, 168(2), 256-272.
Chicago	Sadeghirad H, Bahrami T, Layeghi SM, Yousefi H, Rezaei M, Hosseinifard SR, Radfar P, Warkiani ME, Obyrne K, Kulasinghe A. "Immunotherapeutic Targets in Non-Small Cell Lung Cancer." Immunology 168, no. 2 (2023): 256-272.
Harvard	Sadeghirad H et al. (2023) 'Immunotherapeutic Targets in Non-Small Cell Lung Cancer', Immunology, 168(2), pp. 256-272.
Vancouver	Sadeghirad H, Bahrami T, Layeghi SM, Yousefi H, Rezaei M, Hosseinifard SR, et al.. Immunotherapeutic Targets in Non-Small Cell Lung Cancer. Immunology. 2023;168(2):256-272.
BibTex	@article{ author = {Sadeghirad H and Bahrami T and Layeghi SM and Yousefi H and Rezaei M and Hosseinifard SR and Radfar P and Warkiani ME and Obyrne K and Kulasinghe A}, title = {Immunotherapeutic Targets in Non-Small Cell Lung Cancer}, journal = {Immunology}, volume = {168}, number = {2}, pages = {256-272}, year = {2023} }
RIS	TY - JOUR AU - Sadeghirad H AU - Bahrami T AU - Layeghi SM AU - Yousefi H AU - Rezaei M AU - Hosseinifard SR AU - Radfar P AU - Warkiani ME AU - Obyrne K AU - Kulasinghe A TI - Immunotherapeutic Targets in Non-Small Cell Lung Cancer JO - Immunology VL - 168 IS - 2 SP - 256 EP - 272 PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract